BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21185177)

  • 1. Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.
    Noël R; Shin Y; Song X; He Y; Koenig M; Chen W; Ling YY; Lin L; Ruiz CH; LoGrasso P; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2011 May; 21(9):2732-5. PubMed ID: 21185177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
    Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.
    Humphries PS; Lafontaine JA; Agree CS; Alexander D; Chen P; Do QQ; Li LY; Lunney EA; Rajapakse RJ; Siegel K; Timofeevski SL; Wang T; Wilhite DM
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2099-102. PubMed ID: 19327989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
    Palmer WS; Alam M; Arzeno HB; Chang KC; Dunn JP; Goldstein DM; Gong L; Goyal B; Hermann JC; Hogg JH; Hsieh G; Jahangir A; Janson C; Jin S; Ursula Kammlott R; Kuglstatter A; Lukacs C; Michoud C; Niu L; Reuter DC; Shao A; Silva T; Trejo-Martin TA; Stein K; Tan YC; Tivitmahaisoon P; Tran P; Wagner P; Weller P; Wu SY
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1486-92. PubMed ID: 23352510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
    Dwyer MP; Keertikar K; Paruch K; Alvarez C; Labroli M; Poker C; Fischmann TO; Mayer-Ezell R; Bond R; Wang Y; Azevedo R; Guzi TJ
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6178-82. PubMed ID: 24091081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
    Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation.
    Zhang Y; Liu Y; Zhou Y; Zhang Q; Han T; Tang C; Fan W
    Bioorg Med Chem Lett; 2021 Jan; 31():127712. PubMed ID: 33246108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors.
    He Y; Kamenecka TM; Shin Y; Song X; Jiang R; Noel R; Duckett D; Chen W; Ling YY; Cameron MD; Lin L; Khan S; Koenig M; LoGrasso PV
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1719-23. PubMed ID: 21316221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
    Wolle P; Hardick J; Cronin SJF; Engel J; Baumann M; Lategahn J; Penninger JM; Rauh D
    J Med Chem; 2019 Mar; 62(5):2843-2848. PubMed ID: 30768270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.
    Abdelazem AZ; Al-Sanea MM; Park BS; Park HM; Yoo KH; Sim T; Park JB; Lee SH; Lee SH
    Eur J Med Chem; 2015 Jan; 90():195-208. PubMed ID: 25461320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrazole derivatives as potent inhibitors of c-Jun N-terminal kinase: synthesis and SAR studies.
    Doma A; Kulkarni R; Palakodety R; Sastry GN; Sridhara J; Garlapati A
    Bioorg Med Chem; 2014 Nov; 22(21):6209-19. PubMed ID: 25261929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
    Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
    Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.
    Kamenecka T; Jiang R; Song X; Duckett D; Chen W; Ling YY; Habel J; Laughlin JD; Chambers J; Figuera-Losada M; Cameron MD; Lin L; Ruiz CH; LoGrasso PV
    J Med Chem; 2010 Jan; 53(1):419-31. PubMed ID: 19947601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.